Literature DB >> 5051662

Combination chemotherapy for multiple myeloma.

R Alexanian, J Bonnet, E Gehan, A Haut, J Hewlett, M Lane, R Monto, H Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5051662     DOI： 10.1002/1097-0142(197208)30:2<382::aid-cncr2820300213>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  27 in total

1.  [Unusual location of extramedullary plasmacytomas (author's transl)].

Authors:  A Schmitt-Gräff; W Arnold
Journal:  Arch Otorhinolaryngol       Date:  1979

2.  Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.

Authors:  Jeremy T Larsen; Cheng E Chee; John A Lust; Philip R Greipp; S Vincent Rajkumar
Journal:  Blood       Date:  2011-07-12       Impact factor: 22.113

Review 3.  Multiple myeloma: current treatment.

Authors:  D Samson
Journal:  Postgrad Med J       Date:  1994-06       Impact factor: 2.401

4.  Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients.

Authors:  Karen Shires; Kirsty Wienand
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-31       Impact factor: 4.553

5.  VAD protocol for treatment of advanced refractory multiple myeloma.

Authors:  W Scheithauer; A Cortelezzi; R Kutzmits; L Baldini; H Ludwig
Journal:  Blut       Date:  1987-09

6.  Blood and neoplastic diseases. Myelomatosis.

Authors:  J S Malpas
Journal:  Br Med J       Date:  1974-11-30

7.  Controversies in the treatment of plasma cell myeloma.

Authors:  D E Bergsagel
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

8.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.

Authors:  B Steinke; F W Busch; C Becherer; P Ostendorf; H D Waller
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Long-term survival in multiple myeloma: a single-center experience.

Authors:  Francesca Merchionne; Pasquale Procaccio; Franco Dammacco
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.